Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
1
|
Sorafenib in advanced hepatocellular carcinoma.
|
N Engl J Med
|
2008
|
54.30
|
2
|
Gene expression in fixed tissues and outcome in hepatocellular carcinoma.
|
N Engl J Med
|
2008
|
9.20
|
3
|
Hepatocellular carcinoma: clinical frontiers and perspectives.
|
Gut
|
2014
|
5.79
|
4
|
Resection of hepatocellular cancer ≤2 cm: results from two Western centers.
|
Hepatology
|
2013
|
5.05
|
5
|
Resection and liver transplantation for hepatocellular carcinoma.
|
Semin Liver Dis
|
2005
|
4.51
|
6
|
Focal gains of VEGFA and molecular classification of hepatocellular carcinoma.
|
Cancer Res
|
2008
|
4.35
|
7
|
Comparative efficacy of sorafenib versus best supportive care in recurrent hepatocellular carcinoma after liver transplantation: a case-control study.
|
J Hepatol
|
2013
|
4.28
|
8
|
miR-221 overexpression contributes to liver tumorigenesis.
|
Proc Natl Acad Sci U S A
|
2009
|
4.15
|
9
|
Pivotal role of mTOR signaling in hepatocellular carcinoma.
|
Gastroenterology
|
2008
|
4.03
|
10
|
Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma.
|
Hepatology
|
2007
|
3.85
|
11
|
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial.
|
J Hepatol
|
2012
|
3.04
|
12
|
Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma.
|
Gastroenterology
|
2011
|
2.66
|
13
|
Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo.
|
J Hepatol
|
2009
|
2.42
|
14
|
Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes.
|
Gastroenterology
|
2013
|
2.42
|
15
|
Gene-expression signature of vascular invasion in hepatocellular carcinoma.
|
J Hepatol
|
2011
|
2.39
|
16
|
A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis.
|
Gastroenterology
|
2006
|
2.32
|
17
|
Downregulation of KLF6 is an early event in hepatocarcinogenesis, and stimulates proliferation while reducing differentiation.
|
J Hepatol
|
2006
|
1.98
|
18
|
Heterogeneity of patients with intermediate (BCLC B) Hepatocellular Carcinoma: proposal for a subclassification to facilitate treatment decisions.
|
Semin Liver Dis
|
2013
|
1.85
|
19
|
MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a.
|
Gastroenterology
|
2011
|
1.77
|
20
|
Personalized molecular targeted therapy in advanced, recurrent hepatocellular carcinoma after liver transplantation: a proof of principle.
|
J Hepatol
|
2010
|
1.77
|
21
|
Prophylaxis of hepatitis B virus recurrence after liver transplantation in carriers of lamivudine-resistant mutants.
|
Liver Transpl
|
2005
|
1.68
|
22
|
IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage.
|
J Hepatol
|
2010
|
1.66
|
23
|
Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial.
|
Transplantation
|
2016
|
1.59
|
24
|
Liver Match, a prospective observational cohort study on liver transplantation in Italy: study design and current practice of donor-recipient matching.
|
Dig Liver Dis
|
2010
|
1.54
|
25
|
The place of liver transplantation in the treatment of hepatic epitheloid hemangioendothelioma: report of the European liver transplant registry.
|
Ann Surg
|
2007
|
1.51
|
26
|
Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib.
|
Clin Cancer Res
|
2012
|
1.44
|
27
|
Massive APOBEC3 editing of hepatitis B viral DNA in cirrhosis.
|
PLoS Pathog
|
2010
|
1.43
|
28
|
Liver transplantation for unresectable hepatocellular carcinoma in normal livers.
|
J Hepatol
|
2012
|
1.42
|
29
|
Yttrium 90 radioembolization for the treatment of hepatocellular carcinoma: biological lessons, current challenges, and clinical perspectives.
|
Hepatology
|
2013
|
1.23
|
30
|
Heat shock proteins: biological functions and clinical application as personalized vaccines for human cancer.
|
Cancer Immunol Immunother
|
2003
|
1.20
|
31
|
Role of the multidisciplinary team in the diagnosis and treatment of hepatocellular carcinoma.
|
Expert Rev Gastroenterol Hepatol
|
2012
|
1.14
|
32
|
Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study.
|
Eur J Cancer
|
2013
|
1.12
|
33
|
Helicobacter species sequences in liver samples from patients with and without hepatocellular carcinoma.
|
World J Gastroenterol
|
2004
|
1.08
|
34
|
Chromosome instability in human hepatocellular carcinoma depends on p53 status and aflatoxin exposure.
|
Mutat Res
|
2008
|
1.08
|
35
|
A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma.
|
BMC Cancer
|
2010
|
1.06
|
36
|
Human tumor-derived heat shock protein 96 mediates in vitro activation and in vivo expansion of melanoma- and colon carcinoma-specific T cells.
|
J Immunol
|
2003
|
1.06
|
37
|
Summary of candidate selection and expanded criteria for liver transplantation for hepatocellular carcinoma: a review and consensus statement.
|
Liver Transpl
|
2011
|
1.02
|
38
|
Percutaneous transhepatic biliary drainage in the management of postsurgical biliary leaks in patients with nondilated intrahepatic bile ducts.
|
Cardiovasc Intervent Radiol
|
2006
|
1.02
|
39
|
Relationship between baseline hepatic status and outcome, and effect of sorafenib on liver function: SHARP trial subanalyses.
|
J Hepatol
|
2012
|
1.01
|
40
|
Fibroblastic reticular cell tumor of the spleen: report of a case and review of the entity.
|
Hum Pathol
|
2003
|
0.99
|
41
|
Prognostic role of pancreatic metastases from renal cell carcinoma: results from an Italian center.
|
Clin Genitourin Cancer
|
2013
|
0.97
|
42
|
Duodenal fistula after elective gastrectomy for malignant disease : an italian retrospective multicenter study.
|
J Gastrointest Surg
|
2010
|
0.97
|
43
|
Split and whole liver transplantation outcomes: a comparative cohort study.
|
Liver Transpl
|
2006
|
0.95
|
44
|
Importance of early nutritional screening in patients with gastric cancer.
|
Br J Nutr
|
2011
|
0.91
|
45
|
Transarterial chemoembolization for hepatocellular carcinoma with a new generation of beads: clinical-radiological outcomes and safety profile.
|
Cardiovasc Intervent Radiol
|
2014
|
0.90
|
46
|
The challenges of liver transplantation for hepatocellular carcinoma on cirrhosis.
|
Transpl Int
|
2010
|
0.89
|
47
|
Evidence of distinct tumour-propagating cell populations with different properties in primary human hepatocellular carcinoma.
|
PLoS One
|
2011
|
0.88
|
48
|
Heat shock proteins and their use as anticancer vaccines.
|
Clin Cancer Res
|
2004
|
0.87
|
49
|
Feasibility of peritonectomy associated with intraperitoneal hyperthermic perfusion in patients with Pseudomyxoma peritonei.
|
Tumori
|
2002
|
0.86
|
50
|
Resting energy expenditure in diabetic and nondiabetic patients with liver cirrhosis: relation with insulin sensitivity and effect of liver transplantation and immunosuppressive therapy.
|
Am J Clin Nutr
|
2002
|
0.86
|
51
|
Multidisciplinary approach for the treatment of neuroendocrine tumors.
|
Tumori
|
2011
|
0.85
|
52
|
Living donor liver transplantation for hepatocellular carcinoma exceeding conventional criteria: questions, answers and demands for a common language.
|
Liver Transpl
|
2006
|
0.84
|
53
|
Natural killer and NK-Like T-cell activation in colorectal carcinoma patients treated with autologous tumor-derived heat shock protein 96.
|
Cancer Res
|
2005
|
0.84
|
54
|
Partial hepatectomy versus radiofrequency ablation for hepatocellular carcinoma: confirming the trial that will never be, and some comments on the indications for liver resection.
|
Hepatology
|
2010
|
0.84
|
55
|
Intrahepatic flow redistribution in patients treated with radioembolization.
|
Cardiovasc Intervent Radiol
|
2014
|
0.83
|
56
|
Failure of Intravenous Silibinin Monotherapy to Prevent Hepatitis C Genotype 2A Liver Graft Reinfection.
|
Hepat Mon
|
2012
|
0.81
|
57
|
Pathological response after neoadjuvant bevacizumab- or cetuximab-based chemotherapy in resected colorectal cancer liver metastases.
|
Med Oncol
|
2015
|
0.81
|
58
|
Ewing sarcoma of the small bowel: a study of seven cases, including one with the uncommonly reported EWSR1-FEV translocation.
|
Histopathology
|
2014
|
0.81
|
59
|
Liver transplantation for neuroendocrine tumour liver metastases.
|
HPB (Oxford)
|
2014
|
0.80
|
60
|
Simultaneous characterization of progenitor cell compartments in adult human liver.
|
Cytometry A
|
2010
|
0.79
|
61
|
Resection, transplantation, either, or both? Other pieces of the puzzle.
|
Liver Transpl
|
2005
|
0.79
|
62
|
Thyroid as a target of metastases. A case of foregut neuroendocrine carcinoma with multiple abdominal metastases and a thyroid localization after 21 years.
|
Tumori
|
2008
|
0.79
|
63
|
Nonhepatic glucose production in humans.
|
Am J Physiol Endocrinol Metab
|
2003
|
0.78
|
64
|
The dosimetric importance of the number of 90Y microspheres in liver transarterial radioembolization (TARE).
|
Eur J Nucl Med Mol Imaging
|
2014
|
0.78
|
65
|
Etoposide, cisplatin, epirubicin chemotherapy in the treatment of pediatric liver tumors.
|
Pediatr Hematol Oncol
|
2005
|
0.78
|
66
|
A prospective policy development to increase split-liver transplantation for 2 adult recipients: results of a 12-year multicenter collaborative study.
|
Ann Surg
|
2014
|
0.78
|
67
|
Well-differentiated neuroendocrine tumor of tailgut cyst. A rare entity with controversial medical opportunities.
|
Tumori
|
2013
|
0.78
|
68
|
Solid-pseudopapillary tumor of the pancreas (Frantz tumor) in children.
|
Med Pediatr Oncol
|
2003
|
0.77
|
69
|
Amino acid kinetics during the anhepatic phase of liver transplantation.
|
Diabetes
|
2002
|
0.77
|
70
|
Transhepatic anterior approach to the inferior vena cava in large retroperitoneal tumors resected en bloc with the right liver lobe.
|
Surgery
|
2013
|
0.77
|
71
|
When should a liver resection be performed in patients with liver metastases from neuroendocrine tumours? A systematic review with practice recommendations.
|
HPB (Oxford)
|
2014
|
0.76
|
72
|
Transthyretin RNA profiling in livers from transplanted patients affected by familial amyloidotic polyneuropathy, and identification of a dual transcription start point.
|
Liver Int
|
2006
|
0.75
|
73
|
Reply:.
|
Hepatology
|
2013
|
0.75
|
74
|
Liver retransplantation in adults: the largest multicenter Italian study.
|
PLoS One
|
2012
|
0.75
|
75
|
Exploiting liver immunity for the prevention of hepatic metastases.
|
J Hepatol
|
2010
|
0.75
|
76
|
Succinate dehydrogenase B subunit immunohistochemical expression predicts aggressiveness in well differentiated neuroendocrine tumors of the ileum.
|
Cancers (Basel)
|
2012
|
0.75
|
77
|
Preoperative Capecitabine, Oxaliplatin, and Irinotecan in Resectable Gastric or Gastroesophageal Junction Cancer: Pathological Response as Primary Endpoint and FDG-PET Predictions.
|
Oncology
|
2017
|
0.75
|
78
|
Candidates for liver transplantation for cancer: physical, psychological, and social conditions.
|
Transplantation
|
2002
|
0.75
|
79
|
CT cholangiography: assessment of feasibility and diagnostic reliability.
|
Eur J Radiol
|
2008
|
0.75
|
80
|
HEPATIC EPITHELIOID HEMANGIO-ENDOTHELIOMA AND ADULT LIVER TRANSPLANTATION: PROPOSAL FOR A PROGNOSTIC SCORE BASED ON THE ANALYSIS OF THE ELTR-ELITA REGISTRY.
|
Transplantation
|
2016
|
0.75
|
81
|
Assessment of insulin sensitivity based on a fasting blood sample in men with liver cirrhosis before and after liver transplantation.
|
Transplantation
|
2003
|
0.75
|
82
|
Management of biliary anastomotic strictures after liver transplantation (BASALT study): A nationwide Italian survey.
|
Liver Transpl
|
2017
|
0.75
|
83
|
Hepatic Epithelioid Hemangioendothelioma and Adult Liver Transplantation: Proposal for a Prognostic Score Based on the Analysis of the ELTR-ELITA Registry.
|
Transplantation
|
2017
|
0.75
|